Abstract: The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists.

Abstract: Drug disposal devices and systems for reducing the amount of drug contained in a transdermal drug delivery patch are disclosed. The drug disposal devices contain an adsorbing substance, such as activated carbon, and are capable of adsorbing residual drug from the transdermal patch and preventing back-extraction of the drug. Also disclosed are methods of manufacturing the drug disposal devices and methods of using the drug disposal devices for reducing the amount of drug contained within a transdermal drug delivery patch.

Abstract: The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists.

Abstract: A novel dosage form for delivering an opioid antagonist such as naloxone is disclosed. The dosage form comprises an oral dissolvable film containing an amount of the opioid antagonist effective to reduce or counteract the effect of an opioid overdose in an individual. Methods of administering the dosage form to an individual experiencing an opioid overdose are also disclosed.

Abstract: Transdermal drug delivery devices and systems with improved adhesion are disclosed. The transdermal drug delivery devices, or patches, include an integrated overlay that provides a drug-free adhesive perimeter designed to avoid affecting delivery of drug from the device. Also disclosed are methods of manufacturing the transdermal drug delivery devices that include incorporating an integrated overlay onto a TDS patch.

Abstract: Drug disposal devices and systems for reducing the amount of drug contained in a transdermal drug delivery patch are disclosed. The drug disposal devices contain an adsorbing substance, such as activated carbon, and are capable of adsorbing residual drug from the transdermal patch and preventing back-extraction of the drug. Also disclosed are methods of manufacturing the drug disposal devices and methods of using the drug disposal devices for reducing the amount of drug contained within a transdermal drug delivery patch.

Abstract: Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing rasagiline for the treatment of depression, Parkinson's disease, and other nervous system conditions.

Abstract: Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing selegiline base for the treatment of depression, Parkinson's disease, and other nervous system conditions.

Abstract: Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing selegiline base for the treatment of depression, Parkinson's disease, and other nervous system conditions.

Abstract: Transdermal delivery systems for delivery of Alzheimer's pharmaceuticals, particularly donepezil, over one to seven days are disclosed which deliver the free-base form of the Alzheimer's pharmaceutical at a skin permeation rate such that blood levels of the Alzheimer's pharmaceuticals are comparable to the approved oral dosage forms.

Abstract: The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists.

Abstract: The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists.

Abstract: The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists.

Abstract: Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing selegiline base for the treatment of depression, Parkinson's disease, and other nervous system conditions.

Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.

Abstract: Transdermal delivery systems for delivery of Alzheimer's pharmaceuticals, particularly donepezil, over one to seven days are disclosed which deliver the free-base form of the Alzheimer's pharmaceutical at a skin permeation rate such that blood levels of the Alzheimer's pharmaceuticals are comparable to the approved oral dosage forms.

Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.

Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.

Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.

Abstract: The present invention provides a method for treating Alzheimer's Disease using a xanomeline transdermal formulation. The invention provides desired transdermal xanomeline patch formulations.